Skip to main content
Holger Eltzschig, MD, Anesthesiology, Houston, TX, Memorial Hermann - Texas Medical Center

HolgerEltzschigMD

Anesthesiology Houston, TX

Professor, Anesthesiology, University of Colorado School of Medicine

Are you Dr. Eltzschig?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

  • Connect with colleagues in the same hospital or clinic
    You already have 49 invites waiting!
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

Claim this profile

Not you? Find your profile

Summary

  • Dr. Holger Eltzschig, MD is a board certified anesthesiologist in Houston, Texas. He is currently licensed to practice medicine in Texas, Colorado, and Massachusetts. He is affiliated with Memorial Hermann - Texas Medical Center and is a Professor at University of Colorado School of Medicine.

Education & Training

  • Brigham and Women's Hospital
    Brigham and Women's HospitalResidency, Anesthesiology, 1999 - 2002
  • Eberhard Karls University Faculty of Medicine
    Eberhard Karls University Faculty of MedicineClass of 1996

Certifications & Licensure

  • CO State Medical License
    CO State Medical License 2007 - 2025
  • MA State Medical License
    MA State Medical License 2002 - 2025
  • TX State Medical License
    TX State Medical License 2017 - 2024
  • American Board of Anesthesiology Anesthesiology

Awards, Honors, & Recognition

  • Elected Member The American Society for Clinical Investigation, 2011

Publications & Presentations

PubMed

Authored Content

  • Anesthetic Drugs and Cancer Progression: Fact or FictionAugust 2020

Press Mentions

  • DOD Injects $5.1m into Clinical Trial Investigating Novel Oral Therapy to Treat ARDS Associated with COVID-19
    DOD Injects $5.1m into Clinical Trial Investigating Novel Oral Therapy to Treat ARDS Associated with COVID-19January 14th, 2021
  • Researchers Receive $5.1 Million to Expand Clinical Trial of Drug to Prevent ARDS in COVID-19 Patients
    Researchers Receive $5.1 Million to Expand Clinical Trial of Drug to Prevent ARDS in COVID-19 PatientsJanuary 13th, 2021
  • GATA Factor-Regulated Solute Carrier Ensemble Reveals a Nucleoside Transporter-Dependent Differentiation Mechanism
    GATA Factor-Regulated Solute Carrier Ensemble Reveals a Nucleoside Transporter-Dependent Differentiation MechanismDecember 28th, 2020
  • Join now to see all

Hospital Affiliations